Medically reviewed on Nov 15, 2018
(al bi GLOO tide)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Pen-injector, Subcutaneous [preservative free]:
Tanzeum: 30 mg (1 ea [DSC]); 50 mg (1 ea [DSC]) [contains polysorbate 80]
Brand Names: U.S.
- Tanzeum [DSC]
- Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
Albiglutide is an agonist of human glucagon-like peptide-1 (GLP-1) receptor and augments glucose-dependent insulin secretion and slows gastric emptying.
Vd: 11 L
Degradation to small peptides and individual amino acids by proteolytic enzymes.
Time to Peak
3 to 5 days
Use: Labeled Indications
Diabetes mellitus, type 2: Adjunct to diet and exercise to improve glycemic control in the treatment of type 2 diabetes mellitus
Prior serious hypersensitivity (eg, angioedema) to albiglutide or any component of the formulation; history of or family history of medullary thyroid carcinoma (MTC); patients with multiple endocrine neoplasia syndrome type 2 (MEN2)
Diabetes mellitus, type 2: SubQ: 30 mg once weekly; may increase to 50 mg once weekly if inadequate glycemic response. Titration to 50 mg once weekly occurred at week 12 in a monotherapy trial and after a minimum of 4 weeks in combination therapy trials.
Concomitant use with insulin and/or insulin secretagogues (eg, sulfonylurea): Reduced dose of insulin and/or insulin secretagogues may be needed.
Missed doses: If a dose is missed, administer as soon as possible within 3 days after the missed dose; dosing can then be resumed on the usual day of administration. If more than 3 days have passed since the dose was missed, omit the missed dose and resume administration at the next regularly scheduled weekly dose.
Refer to adult dosing.
Dosing: Renal Impairment
eGFR ≥15 to 89 mL/minute/1.73 m2: No dosage adjustment necessary; use caution when initiating or escalating doses.
eGFR <15 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, changes in hepatic function are not likely to have an effect on elimination.
Reconstitute powder with the diluent contained in the pen device. Refer to manufacturer's product labeling for full reconstitution instructions. Administer within 8 hours of reconstitution.
SubQ: Do not inject intravenously or intramuscularly. Inject subcutaneously into the upper arm, thigh, or abdomen; when administering within the same body region, use a different injection site each week. Administer once weekly on the same day each week, without regard to meals or time of day. The day of weekly administration may be changed, as long as the last dose was administered ≥4 days before. Use immediately after attaching and priming the needle; solution can clog the needle if allowed to dry in the primed needle. If using concomitantly with insulin, administer as separate injections (do not mix); may inject in the same body region as insulin, but not adjacent to one another.
Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.
Store unused pens at 2°C to 8°C (36°F to 46°F); may be stored at room temperature (≤30°C [86°F]) for ≤4 weeks prior to reconstitution. Do not freeze. Use within 8 hours of reconstitution.
Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Monitor therapy
Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol. Monitor therapy
Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Monitor therapy
Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Monitor therapy
Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Monitor therapy
Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea. Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Monitor therapy
Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Monitor therapy
Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea. Consider therapy modification
Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Monitor therapy
Reactions reported from monotherapy and combination therapy.
Endocrine & metabolic: Hypoglycemia (combination therapy; 3% to 17%)
Gastrointestinal: Diarrhea (13%), nausea (11%)
Local: Injection site reaction (11% to 18%, including erythema at injection site [2%], hypersensitivity reaction at injection site [1%], rash at injection site [1%], itching at injection site)
Respiratory: Upper respiratory tract infection (14%)
1% to 10%:
Cardiovascular: Atrial fibrillation (1%)
Endocrine & metabolic: Increased gamma-glutamyl transferase (2%)
Gastrointestinal: Gastroesophageal reflux disease (4%), vomiting (4%)
Immunologic: Antibody development (non-neutralizing; 6%)
Infection: Influenza (5%)
Neuromuscular & skeletal: Arthralgia (7%), back pain (7%)
Respiratory: Cough (7%), pneumonia (2%)
<1%: Angioedema, appendicitis, atrial flutter, constipation, hypersensitivity reaction, increased heart rate (1-2 bpm), increased serum ALT, increased serum bilirubin, pancreatitis
Concerns related to adverse effects:
• Hypersensitivity reactions: Serious hypersensitivity reactions (including angioedema, generalized pruritus and rash with dyspnea) have been reported with use; discontinue therapy in the event of a hypersensitivity reaction; treat appropriately and monitor patients until signs and symptoms resolve. Use in patients with prior serious hypersensitivity reactions to albiglutide is contraindicated. Use with caution in patients with history of anaphylaxis or angioedema to other GLP-1 receptor agonists; potential for cross-sensitivity is unknown.
• Gallbladder disease: Use of GLP-1 agonists may increase risk of gallbladder and bile duct disease (Faillie 2016).
• Pancreatitis: Cases of acute pancreatitis have been reported; monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain which may radiate to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue use. Do not resume unless an alternative etiology of pancreatitis is confirmed. Consider antidiabetic therapies other than albiglutide in patients with a history of pancreatitis.
• Renal effects: Worsening renal failure and acute kidney injury (some requiring hemodialysis) have been reported; some cases have been reported in patients with no known preexisting renal disease and without gastrointestinal adverse reactions. Monitor for dehydration associated with gastrointestinal effects and avoid fluid depletion.
• Thyroid tumors: [US Boxed Warning] Thyroid C-cell tumors have developed in animal studies with glucagon-like peptide-1 (GLP-1) receptor agonists; it is not known if albiglutide causes thyroid C-cell tumor, including medullary thyroid carcinoma (MTC) in humans. Routine monitoring of serum calcitonin or using thyroid ultrasound monitoring is of uncertain value for early detection of MTC in patients treated with albiglutide. Patients should be counseled on the potential risk of MTC with the use of albiglutide and informed of symptoms of thyroid tumors (eg, neck mass, dysphagia, dyspnea, persistent hoarseness). Use is contraindicated in patients with a personal or a family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN2). Cases of MTC in humans have been reported in patients treated with the GLP-1 receptor agonist liraglutide. Consultation with an endocrinologist is recommended in patients with thyroid nodules on physical examination or neck imaging and patients who develop elevated calcitonin concentrations.
• Gastrointestinal disease: Use is not recommended in patients with preexisting severe gastrointestinal disease.
• Renal impairment: Use with caution in patients with renal impairment and/or in patients with severe GI symptoms, particularly during initiation of therapy and dose escalation.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Appropriate use: Diabetes mellitus: Not recommended for first-line therapy in patients inadequately controlled on diet and exercise alone. Do not use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; not a substitute for insulin.
• Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.
Plasma glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a]), renal function, signs/symptoms of pancreatitis; signs/symptoms of gallbladder disease; signs/symptoms of dehydration
Pregnancy Risk Factor
Adverse events have been observed in some animal reproduction studies.
In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and Hb1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013). Agents other than albiglutide are currently recommended to treat diabetes in pregnant women (ADA 2018c).
Because of the long washout period, consider stopping albiglutide at least 1 month before a planned pregnancy.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience diarrhea, nausea, injection site irritation, back pain, joint pain, cough, flu-like symptoms, or common cold symptoms. Have patient report immediately to prescriber signs of thyroid cancer (new lump or swelling in the neck, pain in the front of the neck, persistent cough, persistent change in voice like hoarseness, or difficulty swallowing or breathing), signs of pancreatitis (severe abdominal pain, severe back pain, severe nausea, or vomiting), signs of kidney problems (urinary retention, hematuria, change in amount of urine passed, or weight gain), dizziness, passing out, or signs of low blood sugar (dizziness, headache, fatigue, feeling weak, shaking, tachycardia, confusion, increased hunger, or sweating) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about albiglutide
- Albiglutide Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 11 Reviews
- Drug class: incretin mimetics
Other brands: Tanzeum